Original Research

Assessing Refill Data Among Different Classes of Antidepressants

No significant difference was seen in between-class adherence when comparing SSRIs, SNRIs, bupropion, and mirtazapine during a 3-month study of veterans newly initiated on antidepressants.

Author and Disclosure Information

 

Depression affects about 4.4% of the global population. 1 Major depressive disorder (MDD) is currently the fourth highest cause of disability in the world and by 2030 MDD is expected to be third. 2 Research has determined that 1 in 3 veterans seen in primary care shows depressive symptoms. Of these, 1 in 5 have symptoms severe enough to warrant further evaluation for MDD, and 1 in 10 require treatment. 3 With this high rate of depression, optimized treatment strategies are needed, including antidepressants and psychotherapy. Antidepressants have grown in popularity since market entry in the 1950s; currently 1 in 10 US citizens aged ≥ 12 years are prescribed an antidepressant. 4

Click here to continue reading.

Next Article:

Open Clinical Trials for Veterans With Suicidal Ideation

Related Articles